Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
To evaluate the safety and immunogenicity of GSK Biologicals’ live attenuated MMR vaccine (Priorix) in a local population in Singapore. The vaccine was administered as a single dose to healthy children (12-18 months of age) and blood samples were collected at two time points (before vaccination and after vaccination).
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||A Study to Assess the Safety and Immunogenicity of GSK Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00388440
|GSK Clinical Trials Call Center|
|Singapore, Singapore, 688846|
|Study Director:||Clinical Trials||GlaxoSmithKline|